Light chain multiple myeloma: an evaluation of its biochemical investigations

Multiple myeloma is a type of plasma cell dyscrasia, characterised by presence of paraprotein or monoclonal (M)-protein in serum or urine. The M-protein may consist of an intact immunoglobulin, the heavy chain only or the light chain only. The latter, designated as light chain multiple myeloma (LCMM...

Full description

Bibliographic Details
Main Authors: Zahari Sham, Siti Yazmin, Chellappah Thambiah, Subashini, Samsudin, Intan Nureslyna, Lim, Say Min
Format: Article
Language:English
Published: Malaysian Society of Pathologists 2017
Online Access:http://psasir.upm.edu.my/id/eprint/62306/1/Light%20chain%20multiple%20myeloma.pdf
Description
Summary:Multiple myeloma is a type of plasma cell dyscrasia, characterised by presence of paraprotein or monoclonal (M)-protein in serum or urine. The M-protein may consist of an intact immunoglobulin, the heavy chain only or the light chain only. The latter, designated as light chain multiple myeloma (LCMM) makes up almost 20% of myelomas. Clinical manifestation is often heralded by hypercalcaemia, renal impairment, normocytic normochromic anaemia and bone lesions, reflecting end-organ damage, collectively known as the acronym CRAB. In particular, free light chain nephrotoxicity accounts for the high prevalence of renal impairment seen in LCMM. This case illustrates a typical presentation of LCMM with focal discussion on its initial and diagnostic, as well as prognostic biochemical investigations.